By Denny Jacob
Incyte and Novartis Pharma reached a settlement related to litigation initiated by the latter company regarding royalty payments.
Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty rate payable by the company to Novartis on future sales of Jakafi in the U.S. beginning Jan. 1, 2025.
Incyte said the difference of $242.2 million between the total accrued royalties and the total amount it will pay to Novartis will be recorded in its financial statements for the quarter ending June 30.
Incyte and Novartis entered into a collaboration and license agreement in 2009.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 14, 2025 08:30 ET (12:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。